Prudential PLC Has $899,000 Position in Chemed Corporation $CHE

Prudential PLC lowered its holdings in shares of Chemed Corporation (NYSE:CHE) by 48.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,846 shares of the company’s stock after selling 1,732 shares during the period. Prudential PLC’s holdings in Chemed were worth $899,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Acadian Asset Management LLC boosted its stake in Chemed by 69.3% during the 2nd quarter. Acadian Asset Management LLC now owns 250,722 shares of the company’s stock valued at $122,056,000 after purchasing an additional 102,597 shares during the last quarter. Fuller & Thaler Asset Management Inc. lifted its holdings in Chemed by 249.3% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 130,037 shares of the company’s stock worth $80,015,000 after acquiring an additional 92,813 shares during the period. Woodline Partners LP boosted its holdings in shares of Chemed by 2,681.0% in the 1st quarter. Woodline Partners LP now owns 58,178 shares of the company’s stock worth $35,798,000 after buying an additional 56,086 shares during the last quarter. Nuveen LLC purchased a new stake in Chemed during the first quarter worth about $30,527,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Chemed in the 1st quarter worth approximately $26,059,000. 95.85% of the stock is owned by institutional investors.

Chemed Price Performance

CHE stock opened at $441.83 on Monday. The firm has a 50-day moving average of $441.71 and a 200 day moving average of $477.85. The company has a market cap of $6.26 billion, a P/E ratio of 23.36, a PEG ratio of 2.69 and a beta of 0.43. Chemed Corporation has a 1 year low of $408.42 and a 1 year high of $623.60.

Chemed (NYSE:CHE) last posted its earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). The firm had revenue of $624.90 million for the quarter, compared to analysts’ expectations of $626.04 million. Chemed had a return on equity of 25.89% and a net margin of 11.02%.The firm’s revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the company posted $5.64 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, equities research analysts expect that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Monday, November 17th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Monday, November 17th. Chemed’s dividend payout ratio is 12.69%.

Insider Activity at Chemed

In related news, Director Patrick P. Grace sold 150 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total transaction of $69,508.50. Following the completion of the transaction, the director owned 3,397 shares of the company’s stock, valued at $1,574,135.83. This trade represents a 4.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin J. Mcnamara sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $461.28, for a total transaction of $1,383,840.00. Following the completion of the transaction, the chief executive officer owned 96,197 shares of the company’s stock, valued at approximately $44,373,752.16. The trade was a 3.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Oppenheimer lowered their price objective on Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a research note on Thursday, July 31st. Weiss Ratings restated a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Bank of America dropped their price target on Chemed from $610.00 to $595.00 and set a “buy” rating for the company in a research report on Wednesday, September 10th. Royal Bank Of Canada lowered their price target on Chemed from $589.00 to $572.00 and set an “outperform” rating on the stock in a research report on Monday, November 10th. Finally, Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Thursday, October 30th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Chemed currently has an average rating of “Moderate Buy” and a consensus price target of $574.25.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.